Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

PHASE3CompletedINTERVENTIONAL
Enrollment

960

Participants

Timeline

Start Date

April 25, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Vivax MalariaPlasmodium VivaxMalaria, VivaxMalaria Relapse
Interventions
DRUG

Tafenoquine

patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).

DRUG

Primaquine

patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)

Trial Locations (6)

Unknown

Kravanh District Hospital, Pursat

Chambak Health Center, Kampong Speu

Siem Pang Health Centre, Stung Treng

Arba Minch General Hospital, Arba Minch

Tanjung Leidong Health Center, Labuhanbatu

Aga Khan Hospital Karachi, Karachi

All Listed Sponsors
collaborator

University of Melbourne

OTHER

collaborator

National Centre for Parasitology, Entomology and Malaria Control, Cambodia

OTHER

collaborator

Mahidol Oxford Tropical Medicine Research Unit

OTHER

collaborator

Ethiopian Public Health Institute

OTHER_GOV

collaborator

Universitas Sumatera Utara

OTHER

collaborator

Arba Minch University

OTHER

collaborator

Aga Khan University

OTHER

lead

Menzies School of Health Research

OTHER